Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

23.34 +1.14 (+5.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
32 33 Next >
Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday?
Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York. 
Via Benzinga
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
8 Analysts Have This To Say About Sarepta Therapeutics
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
 
Via Benzinga
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with... 
Via StockStory
Discover the top movers in Tuesday's pre-market session.
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor. 
Via Benzinga
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
The patient also had a recent CMV infection, which the company said could have contributed. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was... 
Via StockStory
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in? 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
Via Benzinga
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.